Atlas Trials

Completely Resected NSCLC With Common EGFR Mutations

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Completely Resected NSCLC With Common EGFR Mutations

RecordFirmDate
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. (NCT03381066)Yonsei University2018-04-10

Track Completely Resected NSCLC With Common EGFR Mutations automatically

Every clearance here is in the API, with alerts when new ones post.